Estradiol

Active ingredient: Estradiol

In short: ESTRADIOL TRANSDERMAL SYSTEM is indicated for: Limitation of Use When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis.

Forms & strengthsTransdermal system: 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day.
LabelNoven Therapeutics, LLC
Label updatedNov 16, 2026

What is Estradiol used for?

ESTRADIOL TRANSDERMAL SYSTEM is indicated for:

Limitation of Use

When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis.

âš  Boxed warning (FDA's strongest warning)

There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestogen to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer.

Perform adequate diagnostic measures, including directed or random endometrial sampling when indicated, to rule out malignancy in postmenopausal women with abnormal genital bleeding of unknown etiology .

Estradiol dosage

The timing of ESTRADIOL TRANSDERMAL SYSTEM initiation can affect the overall benefit-risk profile. Consider initiating ESTRADIOL TRANSDERMAL SYSTEM in women < 60 years old or < 10 years since menopause onset .

When estrogen is prescribed for a menopausal woman with a uterus, the addition of a progestogen has been shown to reduce the risk of endometrial cancer. There are possible risks associated with the use of progestogens plus estrogens that differ from those of estrogen-alone regimens. See prescribing information for progestogens indicated for the prevention of endometrial hyperplasia in non-hysterectomized menopausal women receiving estrogens .

Generally, a woman without a uterus does not need to use a progestogen with estrogen therapy. In some cases, however, hysterectomized women with a history of endometriosis may benefit from the addition of a progestogen .

Start therapy with ESTRADIOL TRANSDERMAL SYSTEM 0.0375 mg per day applied to the skin twice weekly. Make dosage adjustments based on clinical response. Reevaluate postmenopausal women periodically as clinically appropriate to determine if treatment is still necessary.

Place the adhesive side of ESTRADIOL TRANSDERMAL SYSTEM on a clean, dry area on the lower abdomen (below the umbilicus) or buttocks. Do not apply ESTRADIOL TRANSDERMAL SYSTEM to the breasts.

Replace ESTRADIOL TRANSDERMAL SYSTEM twice weekly (every 3-4 days).

Rotate the sites of application, with an interval of at least 1 week allowed between applications to a particular site.

Select an area for application that is not oily, damaged, or irritated. Avoid the waistline, since tight clothing may rub the system off. Apply the system immediately after opening the pouch and removing the protective liner. Press the system firmly in place with the palm of the hand for about 10 seconds, making sure there is good contact with the skin, especially around the edges. In the event that a system falls off, reapply the same system or apply a new system to another location. If a woman has forgotten to apply ESTRADIOL TRANSDERMAL SYSTEM, have her apply a new system as soon as possible. Apply the new system on the original treatment schedule. The interruption of treatment in women taking ESTRADIOL TRANSDERMAL SYSTEM might increase the likelihood of breakthrough bleeding, spotting and recurrence of symptoms.

How to take Estradiol — instructions & advice from the label

Advice women to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Vaginal Bleeding

Inform postmenopausal women to report unusual vaginal bleeding to their healthcare providers as soon as possible .

Possible Serious Adverse Reactions with Estrogen–Alone Therapy

Inform postmenopausal women of possible serious adverse reactions of estrogen-alone therapy including Cardiovascular Disorders, Malignant Neoplasms, and Probable Dementia (for persons age 65 years and older) .

Possible Common Adverse Reactions with Estrogen–Alone Therapy

Inform postmenopausal women of less serious but common adverse reactions of estrogen-alone therapy such as headache, breast pain and tenderness, nausea and vomiting.

Warnings & precautions

Do not take this medicine if: ESTRADIOL TRANSDERMAL SYSTEM is contraindicated in women with any of the following conditions:

Abnormal genital bleeding of unknown etiology .

Current or history of breast cancer .

Estrogen-dependent neoplasia .

Active DVT, PE, or a history of these conditions .

Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions .

Known anaphylactic reaction or angioedema or hypersensitivity to ESTRADIOL TRANSDERMAL SYSTEM .

Hepatic impairment or disease .

Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders

ESTRADIOL TRANSDERMAL SYSTEM is contraindicated in women with active DVT, PE, stroke, or a history of these conditions . Immediately discontinue ESTRADIOL TRANSDERMAL SYSTEM if a PE, DVT, or stroke, occurs or is suspected. If feasible, discontinue ESTRADIOL TRANSDERMAL SYSTEM at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization.

The safety and efficacy of ESTRADIOL TRANSDERMAL SYSTEM for the prevention of cardiovascular disorders have not been established.

The Women’s Health Initiative (WHI) estrogen-alone trial reported increased risks of pulmonary embolism (PE), deep vein thrombosis (DVT), and stroke, in postmenopausal women (50 to 79 years of age, average age 63.6 years) during 7.2 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] relative to placebo. Analyses were also conducted in women aged 50-59 years, a group of women more likely to present with new onset of moderate to severe VMS compared to women of other age groups in the trial.

Only daily oral 0.625 mg CE was studied in the WHI estrogen-alone trial. …

Estradiol side effects

The following serious adverse reactions are discussed elsewhere in labeling:

Cardiovascular Disorders

Malignant Neoplasms

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

There were no clinical trials conducted with ESTRADIOL TRANSDERMAL SYSTEM. ESTRADIOL TRANSDERMAL SYSTEM is bioequivalent to Vivelle®. The following adverse reactions are reported with Vivelle therapy:

†Represents milligrams of estradiol delivered daily by each system

*NOS represents not otherwise specified

**NEC represents not elsewhere classified

***Application site erythema and application site irritation were observed in 3.2% or less of patients across treatment groups. …

Drug interactions

In vitro and in vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4 such as St. John’s wort (Hypericum perforatum) preparations, phenobarbital, carbamazepine and rifampin may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile. Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir, and grapefruit juice may increase plasma concentrations of estrogens and may result in adverse reactions.

About this medicine

ESTRADIOL TRANSDERMAL SYSTEM contains estradiol in a multipolymeric adhesive. The system is designed to release estradiol continuously upon application to intact skin.

Five dosage strengths of ESTRADIOL TRANSDERMAL SYSTEM are available to provide nominal in vivo delivery rates of 0.025, 0.0375, 0.05, 0.075, or 0.1 mg of estradiol per day via the skin. Each corresponding system has an active surface area of 1.65, 2.48, 3.30, 4.95, or 6.6 cm2 and contains 0.41, 0.62, 0.83, 1.24, or 1.65 mg of estradiol USP, respectively. The composition of the systems per unit area is identical.

Estradiol USP is a white, crystalline powder, chemically described as estra-1,3,5(10)-triene-3,17β-diol.

The structural formula is

The molecular formula of estradiol is C18H24O2. The molecular weight is 272.39

ESTRADIOL TRANSDERMAL SYSTEM is comprised of three layers. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID bf185599-2138-4083-9c52-2b95dce09ae0. Read the full official label on DailyMed.

Related medicines

Levothyroxine Ergocalciferol Ethinyl Estradiol and Norethindrone Alendronate Testosterone Thyroid Norethindrone Progesterone